Clinical Trials Logo

Brain Injuries, Traumatic clinical trials

View clinical trials related to Brain Injuries, Traumatic.

Filter by:

NCT ID: NCT04810039 Completed - Clinical trials for Prognosis of Neurological Outcome at 6 Months in Patients Undergoing Traumatic Brain Injury

Comparison of the Accuracy of the Neurological Prognosis at 6 Months of Traumatic Brain Injury Between Junior and Senior Doctors

PREDICT II
Start date: March 1, 2021
Phase:
Study type: Observational

PREDICT II is an observational, prospective design, single-center study aiming to determine whether the prognosis of neurological outcome at 6 months in patients undergoing traumatic brain injury established by a doctor at his initial management is more accurate in experienced doctors versus junior doctors.

NCT ID: NCT04806672 Not yet recruiting - Clinical trials for Euthyroid Sick Syndromes in Traumatic Brain Injury Patient and GFAP Level

Euthyroid Sick Syndrome (ESS) Effect on Traumatic Brain Injury Patients and Its Relation With GFAP Level

ESS
Start date: September 1, 2022
Phase:
Study type: Observational

Euthyroid sick syndrome (ESS) effects on patients suffering from traumatic brain injury (TBI) have received little attention. Moreover, there is limited evidence that serum levels of thyroid-related hormones might influence functional outcome in the acute phase of brain damage. However, the relationship is complex, and the relevance for functional outcome and the question of therapeutic interventions remain the subject of ongoing researches . Historically, a wide range of brain damage markers have been examined in TBI patients. However, owing to the limited tissue specificity and other concerns, most markers, including neuro-specific enolase and S100B protein, were compromised in routine clinical use . Glial fibrillary acidic protein (GFAP) was recently reported to have greater prognostic value than other biomarkers in TBI patients as a monomeric intermediate filament protein concentrated in the astroglial cytoskeleton; GFAP is specific to brain tissue and is not routinely found in peripheral blood circulation. However, GFAP is released after astrocyte death, making it an ideal candidate marker for brain injury patients . Several studies have found that the serum levels of GFAP on admission were significantly increased in TBI patients, also a correlation between serum concentrations and the pathological types of brain damage and clinical outcomes were also reported . However, the changes in serum GFAP over time and the associated predictive utility over the acute days post injury are largely unknown. To study the hypothesis of euthyroid sick syndrome (ESS) traumatic brain injury patients and its relation with GFAP.

NCT ID: NCT04798885 Active, not recruiting - Clinical trials for Mild Traumatic Brain Injury

Get Going After concussioN 2.0

GAIN2
Start date: May 12, 2021
Phase: N/A
Study type: Interventional

The study tests the promising results of a previous study (GAIN 1.0) in a larger RCT (GAIN 2.0) which takes place in the municipalities of Central Denmark Region where citizens live their daily lives and whose health- and social care systems support citizens who experience persisting PCS.

NCT ID: NCT04796207 Completed - Clinical trials for Traumatic Brain Injury (TBI)

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

Start date: May 28, 2019
Phase: N/A
Study type: Interventional

Determine if the daily docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) supplement will reduce serum levels of biomarkers of sub-concussion injuries over a course of American football season among collegiate football athletes.

NCT ID: NCT04794894 Enrolling by invitation - Clinical trials for Brain Injuries, Traumatic

Wellness and Quality of Life Perceptions of People With Traumatic Brain Injury

Start date: April 16, 2021
Phase:
Study type: Observational

Telerehabilitation is a service delivery method that has grown substantially in recent years. It has both advantages and disadvantages in comparison to clinic-based services. For example, telerehabilitation is advantageous for people residing in locations in which specialized rehabilitation services are scarce; however, it has the disadvantage of being dependent on reliable internet connections that are not available in all locations. Also, some people prefer the privacy afforded by receiving treatment in their home, but other people prefer the interaction with other clients with similar challenges afforded by attending sessions in clinic-based settings. Other questions about advantages and disadvantages of telerehabilitation remain unexplored. One such question is the focus of this research and concerns the effect of receiving post-acute telerehabilitation services versus clinic-based services on the general well-being and quality of life experienced by people with traumatic brain injury. The study purpose is to compare changes in wellness and quality of life occurring over a four-month period during which people with traumatic brain injury receive post-acute services either via telerehabilitation or at an outpatient facility.

NCT ID: NCT04776304 Completed - PTSD Clinical Trials

Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms

ArtTherapy
Start date: October 30, 2021
Phase: N/A
Study type: Interventional

Service members and/or recently separated veterans with post traumatic stress symptoms and mild traumatic brain injury may participate in 8 sessions including 2 sessions including interviews and questionnaires as well as 6 sessions of art therapy. In the art therapy, participants will be provided with a blank paper mache mask template and invited to alter the mask however they wish using a variety of art materials. The therapist will use the art-making process and culminating product to aid in self-reflection, reframe negative thoughts and feelings, and work through traumatic content. Prior to the session start participants will get set up with a mobile qEEG (worn like a hat and backpack). The qEEG will measure brain activity in a non-invasive way throughout the art therapy session to improve understanding of brain activity during the art therapy process.

NCT ID: NCT04768946 Completed - Stroke Clinical Trials

Using Virtual Technologies to Prevent Injuries in Adolescents With Acquired Brain Injury

Start date: May 1, 2021
Phase:
Study type: Observational

The objective of this study is to identify home safety hazards for adolescents with acquired brain injury and to identify adaptations to the home healthcare virtual simulation training system (HH-VSTS) to improve the user experience for adolescents with ABI

NCT ID: NCT04768192 Recruiting - Clinical trials for Traumatic Brain Injury

Functional and MRI Evaluation of the Robot-assisted and Traditional Rehabilitation Programs on the Muscle

Start date: January 1, 2020
Phase:
Study type: Observational

Walk recovery is one of the goals of rehabilitation programs in patients with acquired brain injury. Recent experiences have shown the effectiveness of rehabilitation programs including traditional physiotherapy in combination with robotic gait training systems (Lokomat). In this context, MRI can be used to assess the treatment effects on the muscular tissue, providing useful clinical indications for the optimization of the rehabilitation programs on the basis of the damage extension and the muscle characteristics.

NCT ID: NCT04766944 Not yet recruiting - Critical Illness Clinical Trials

Incidence and Associated Risk Factors of ARC in the Trauma Critically Ill Older Than 50 Years Old

Start date: March 2024
Phase:
Study type: Observational

This single-center prospective cohort study conducted at the adult trauma ICU of the Montreal General Hospital (MGH) affiliated with the McGill University Health Centre (MUHC) aims to determine the incidence and associated risk factors of augmented renal clearance (ARC) in critically ill trauma patients of 50 years old and above.

NCT ID: NCT04766281 Recruiting - Clinical trials for Moderate Traumatic Brain Injury

MLC901 in Moderate Traumatic Brain Injury

ANDROMEDA
Start date: May 1, 2021
Phase: Phase 4
Study type: Interventional

This study wants to evaluate whether MLC901 will help improve the condition of adult patients with moderate traumatic brain injury.